# US 2016/0256403 A1 · Biocompatible graphene quantum dots for drug delivery and bioimaging applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256403 A1
- Document ID: US20160256403A1
- Status: Published application
- Kind: A1
- Application number: 15/033,513
- Filed: 2014-11-03
- Published: 2016-09-08
- Earliest claimed: 2013-11-01
- Assignees: Council of Scientific and Industrial Research
- Applicants: Council of Scientific and Industrial Research
- Inventors: Neetu Singh; Anil Chandra
- Web page: https://patentgrep.com/patent/US20160256403A1

## CPC

- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 49/0067: {quantum dots, fluorescent nanocrystals}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C01B 32/184: Preparation
- C25B 1/00: Electrolytic production of inorganic compounds or non-metals
- C25B 1/135: Carbon
- C25F 3/02: Etching
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- B82Y 40/00: Manufacture or treatment of nanostructures
- Y10S 977/774: Exhibiting three-dimensional carrier confinement, e.g. quantum dots
- Y10S 977/788: Of specified organic or carbon-based composition
- Y10S 977/888: Shaping or removal of materials, e.g. etching
- Y10S 977/90: having step or means utilizing mechanical or thermal property, e.g. pressure, heat
- Y10S 977/906: Drug delivery
- Y10S 977/927: Diagnostic contrast agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- C25B: ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR (anodic or cathodic protection C23F13/00; single-crystal growth C30B)
- C25F: PROCESSES FOR THE ELECTROLYTIC REMOVAL OF MATERIALS FROM OBJECTS; APPARATUS THEREFOR
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

In this work we have targeted two aspects of GQDs, Size and ROS to reduce their cytotoxicity. Small size can damage cell organelles and production of ROS (reactive oxygen species) can hamper cell machinery in multiple ways. We have shown that cytotoxicity can be significantly reduced by embedding GQDs inside the PEG matrix rather than creating a thin shell around each GQD. Thin PEG shell around GQD can control ROS production but cannot circumvent the toxicity due to small size. Thus it was essential to solve both the issues. We have used a simple electrochemical method (12 h at room temperature) for synthesizing GQDs and embedded them in PEG matrix via a simple one step hydrothermal reaction (24 h at 160° C.) involving only GQDs, PEG, and deionized water. The P-GQDs formed after hydrothermal reaction show nanoparticles of diameter of ˜80-100 nm containing GQDs entrapped in PEG matrix. MTT assay showed significant 60% cells viability at a very high concentration of 5.5 mg/mL of P-GQDs compared to 10-15% viability for C-GQD and H-GQD. ROS production by P-GQDs was least compared to C-GQD and H-GQD in cell free and intracellular ROS assay suggesting involvement of ROS in cytotoxicity. In this work we have solved the issue of cytotoxicity due to ‘small size’ and ‘ROS generation’ without compromising with fluorescence properties of GQDs. P-GQDs was used for bioimaging and drug delivery in HeLa cells. In short we can obtain biocompatible P-GQDs in very short span of time with minimal use of hazardous chemicals and simple methodology.

## Claims

### Claim 1

Biocompatible composition with reduced cytotoxicity comprising graphene quantum dots (GQDs) with a particle size ranging from 5-10 nm embedded in polyethylene glycol (PEG) matrix with a particle size ranging from 80-100 nm, for drug delivery and biomedical applications.

### Claim 2 (depends on 1)

The biocompatible composition as claimed in claim 1, wherein the composition of PEG-GQD at a concentrations of about 8 mg/mL shows up to 50% cell viability when tested on HeLa cell lines.

### Claim 3 (depends on 1)

A process for preparation of biocompatible composition as claimed in claim 1 comprising the steps of:
i. electrochemical etching of multi walled carbon nanotubes at temperature in the range of 25°-28° C. for period in the range of 11 to 12 hrs to provide graphene quantum dots of size 5-10 nm;
ii. mixing graphene quantum dots as obtained in step (i) with polyethylene glycol followed by sonicating at temperature in the range of 20 to 35° C. for period in the range of 25 to 30 minutes to obtain a solution;
iii. autoclaving the solution as obtained in step (ii) at temperature in the range of 140°-180° C. for 23 to 24 hrs and;
iv. cooling at room temperature in the range of 20 to 35° C. followed by dialyzing to obtain biocompatible composition.

### Claim 4 (depends on 3)

The process as claimed in claim 3, wherein the concentration of GQDs embedded in polyethylene glycol is in the range of 1 mg/mL to 4 mg/mL.
